Malignancy	B:C4282132
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	B:C0521174
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	B:C0041618
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	B:C0677607
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	B:C0430445
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	B:C0040137
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	B:C0040137
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	B:C0522580
/	O
FLUS	O
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	B:C1272585
)	O
in	O
cytology	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	O
nodules	I:C0040137
evaluated	O
as	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	B:C1305671
.	O

The	O
predictors	B:C0683956
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	B:C4282132
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B:C0376636
in	O
nodules	O
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	B:C0040137
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	B:C0522580
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	B:C1272585
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	B:C0522580
/	O
FLUS	O
)	O
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	I:C0522580
undetermined	I:C0522580
significance	I:C0522580
/	O
follicular	O
lesion	I:C1272585
of	I:C1272585
undetermined	I:C1272585
significance	I:C1272585
(	O
AUS	O
/	O
FLUS	B:C1272585
)	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	B:C0683956
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	I:C0683956
of	O
malignancy	O
in	O
these	O
patients	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	B:C0683956
,	O
and	O
biochemical	O
predictors	I:C0683956
of	O
malignancy	O
in	O
these	O
patients	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	B:C0683956
predictors	I:C0683956
of	O
malignancy	O
in	O
these	O
patients	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	I:C0683956
of	O
malignancy	B:C4282132
in	O
these	O
patients	O
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	B:C0040137
Bethesda	I:C0040137
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
thyroid	O
nodules	I:C0040137
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	O
Bethesda	I:C0040137
Category	I:C0040137
III	I:C0040137
(	O
AUS	B:C0522580
/	O
FLUS	O
)	O
thyroid	O
nodules	I:C0040137
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	O
Bethesda	I:C0040137
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	B:C1272585
)	O
thyroid	O
nodules	I:C0040137
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	O
Bethesda	I:C0040137
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
thyroid	B:C0040137
nodules	I:C0040137
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	O
Bethesda	I:C0040137
Category	I:C0040137
III	I:C0040137
(	O
AUS	O
/	O
FLUS	O
)	O
thyroid	O
nodules	I:C0040137
were	O
included	O
in	O
this	O
retrospective	B:C0035363
study	I:C0035363
.	O

We	O
divided	O
the	O
nodules	B:C0040137
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	O
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
findings	I:C0243095
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	B:C1257890
according	O
to	O
the	O
histopathology	O
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
findings	I:C0243095
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	B:C0430445
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
findings	I:C0243095
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	O
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	B:C1720195
,	O
clinical	O
,	O
and	O
biochemical	O
findings	I:C0243095
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	O
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	B:C3854293
,	O
and	O
biochemical	O
findings	I:C0243095
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	O
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	B:C0243095
findings	I:C0243095
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	B:C0522580
/	O
FLUS	O
nodules	O
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	B:C1272585
nodules	O
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	O
nodules	B:C0040137
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	O
nodules	O
who	O
had	O
undergone	O
surgery	B:C0543467
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	O
nodules	O
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	B:C4282132
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B:C4282132
was	O
25.8	O
%	O
in	O
nodules	O
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	O
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	B:C0040137
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	O
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	O
with	O
AUS	B:C0522580
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	O
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	O
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	B:C0040137
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	O
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	O
with	O
FLUS	B:C1272585
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B:C0430445
consisted	O
of	O
papillary	O
thyroid	I:C0238463
carcinoma	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinoma	I:C0238463
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	O
consisted	O
of	O
papillary	B:C0238463
thyroid	I:C0238463
carcinoma	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinoma	I:C0238463
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	O
consisted	O
of	O
papillary	O
thyroid	I:C0238463
carcinoma	I:C0238463
(	O
papillary	B:C0238463
thyroid	I:C0238463
carcinoma	I:C0238463
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O

Preoperative	O
ultrasonographic	B:C1720195
features	I:C1720195
of	O
105	O
malignant	O
nodules	I:C0040137
in	O
histopathology	O
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	I:C0749467
in	O
histopathology	O
.	O

Preoperative	O
ultrasonographic	O
features	I:C1720195
of	O
105	O
malignant	B:C0040137
nodules	I:C0040137
in	O
histopathology	O
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	I:C0749467
in	O
histopathology	O
.	O

Preoperative	O
ultrasonographic	O
features	I:C1720195
of	O
105	O
malignant	O
nodules	I:C0040137
in	O
histopathology	B:C0430445
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	I:C0749467
in	O
histopathology	O
.	O

Preoperative	O
ultrasonographic	O
features	I:C1720195
of	O
105	O
malignant	O
nodules	I:C0040137
in	O
histopathology	O
were	O
compared	O
with	O
the	O
344	O
benign	B:C0749467
nodules	I:C0749467
in	O
histopathology	O
.	O

Preoperative	O
ultrasonographic	O
features	I:C1720195
of	O
105	O
malignant	O
nodules	I:C0040137
in	O
histopathology	O
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	I:C0749467
in	O
histopathology	B:C0430445
.	O

Anteroposterior	O
/	O
Transverse	O
(	O
AP/T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	B:C1257890
group	I:C1257890
compared	O
to	O
benign	O
group	I:C1257890
(	O
p	O
=	O
0.013	O
)	O
.	O

Anteroposterior	O
/	O
Transverse	O
(	O
AP/T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	O
group	I:C1257890
compared	O
to	O
benign	B:C1257890
group	I:C1257890
(	O
p	O
=	O
0.013	O
)	O
.	O

In	O
multiple	B:C0936012
logistic	I:C0936012
analysis	I:C0936012
,	O
we	O
found	O
that	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
were	O
independently	O
associated	O
with	O
malignancy	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
multiple	O
logistic	I:C0936012
analysis	I:C0936012
,	O
we	O
found	O
that	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	B:C0521174
were	O
independently	O
associated	O
with	O
malignancy	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
multiple	O
logistic	I:C0936012
analysis	I:C0936012
,	O
we	O
found	O
that	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
were	O
independently	O
associated	O
with	O
malignancy	B:C4282132
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
malignancy	B:C4282132
-	O
associated	O
cut	O
-	O
off	O
value	O
of	O
AP/T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
â‰¥	O
0.81	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	B:C4282132
and	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	O
and	O
Hashimoto	B:C0677607
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	O
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	O
and	O
Hashimoto	O
's	I:C0677607
thyroiditis	I:C0677607
in	O
histopathology	B:C0430445
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
Bethesda	B:C0040137
Category	I:C0040137
III	I:C0040137
nodules	I:C0040137
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	O
-	I:C1510483
needle	I:C1510483
aspiration	I:C1510483
biopsy	I:C1510483
or	O
observation	O
.	O

In	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
nodules	I:C0040137
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	B:C0521174
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	O
-	I:C1510483
needle	I:C1510483
aspiration	I:C1510483
biopsy	I:C1510483
or	O
observation	O
.	O

In	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
nodules	I:C0040137
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	B:C0543467
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	O
-	I:C1510483
needle	I:C1510483
aspiration	I:C1510483
biopsy	I:C1510483
or	O
observation	O
.	O

In	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
nodules	I:C0040137
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	B:C1510483
-	I:C1510483
needle	I:C1510483
aspiration	I:C1510483
biopsy	I:C1510483
or	O
observation	O
.	O

In	O
Bethesda	O
Category	I:C0040137
III	I:C0040137
nodules	I:C0040137
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	O
-	I:C1510483
needle	I:C1510483
aspiration	I:C1510483
biopsy	I:C1510483
or	O
observation	B:C0302523
.	O

